News >

Oncolytic Poliovirus Shows Sustained Survival Rates for Recurrent GBM

Silas Inman @silasinman
Published: Tuesday, Jun 26, 2018

Dr. Eric Van Cutsem

Darell D. Bigner, MD, PhD

Treatment with the recombinant oncolytic poliovirus PVSRIPO elicited a sustained 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma (GBM), according to phase I findings published in the New England Journal of Medicine (NEJM).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication